세계의 진폐증 시장 보고서(2025년)
Pneumoconiosis Global Market Report 2025
상품코드 : 1760694
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

진폐증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 8.0%의 연평균 성장률로 76억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장의 원동력은 산업 보건 기준에 대한 관심 증가, 먼지 규제 강화, 근로자 안전 조치에 대한 투자 증가, 진폐증 위험에 대한 인식 증가, 조기 진단 서비스에 대한 접근성 향상 등입니다. 예측 기간 동안 예상되는 주요 동향으로는 폐 영상 기술의 발전, 휴대용 호흡기 장치의 혁신, AI를 통한 질병 감지 개발, 먼지 관련 건강 문제에 대한 R&D 자금 증가, 웨어러블 공기질 모니터링 센서의 발전 등이 있습니다.

흡연의 확산은 폐암 시장의 성장을 촉진할 것으로 예상됩니다. 흡연은 담배, 시가, 파이프 등 담배 제품을 태운 연기를 흡입하거나 내뿜는 행위로, 폐, 심장, 건강 전반에 악영향을 미치는 유해한 화학제품을 방출합니다. 흡연율의 증가는 다양한 연령층에서 니코틴 중독의 증가와 담배 사용의 지속으로 이어지고 있습니다. 흡연은 흡연과 관련된 폐 질환의 발생률을 증가시킴으로써 진폐증의 원인이 되고 있습니다. 예를 들어, 2023년 6월 가디언지의 보도에 따르면 2023년 초 영국에서 14-17세 청소년의 14.5%가 전자담배 제품을 사용하고 있으며, 이는 2022년 11.8%에서 증가한 수치입니다. 이러한 흡연율의 증가는 폐렴 시장을 발전시키고 있습니다.

헬스케어 지출의 증가는 폐렴 시장 성장에 기여할 것으로 예상됩니다. 헬스케어 지출은 개인, 정부 및 조직이 의료 서비스, 치료 및 건강 관련 제품에 지출하는 총 비용입니다. 의료비 지출의 증가는 주로 지속적인 치료와 관리가 필요한 만성질환의 유병률 증가에 기인합니다. 이러한 지출은 조기 진단, 지속적인 의료, 호흡기 치료, 전문 치료 및 약물에 대한 접근에 자금을 지원함으로써 폐렴 치료를 지원하고 있습니다. 예를 들어, 2024년 5월 영국 통계청이 발표한 바에 따르면, 영국의 의료비 지출은 2022-2023년 사이에 5.6% 증가하여 2022년의 0.9% 증가에 비해 크게 증가하였습니다. 따라서 의료비 지출의 증가는 폐렴 시장의 성장을 가속화할 것으로 보입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

ksm
영문 목차

영문목차

Pneumoconiosis refers to a group of lung diseases resulting from the prolonged inhalation of certain types of dust, leading to inflammation and scarring in the lung tissue. This damage can hinder the lungs' ability to efficiently exchange oxygen, causing symptoms such as shortness of breath, persistent coughing, and reduced exercise tolerance.

The primary types of pneumoconiosis include asbestosis, berylliosis, byssinosis, coal workers' pneumoconiosis, silicosis, and others. Asbestosis is a chronic condition caused by the prolonged inhalation of asbestos fibers. Treatment options for pneumoconiosis include medications, oxygen therapy, pulmonary rehabilitation, and others. These treatments may be administered orally, through inhalation, or other methods, while diagnostic approaches involve chest X-rays, computed tomography (CT) scans, lung function tests, and bronchoscopy. Various healthcare providers, such as hospitals, specialty clinics, and diagnostic centers, serve as end users for these treatments and diagnostic procedures.

The pneumoconiosis market research report is one of a series of new reports from The Business Research Company that provides pneumoconiosis market statistics, including the pneumoconiosis industry global market size, regional shares, competitors with the pneumoconiosis market share, detailed pneumoconiosis market segments, market trends, and opportunities, and any further data you may need to thrive in the pneumoconiosis industry. This pneumoconiosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumoconiosis market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing occupational exposure to coal dust, rising mining activities in unregulated regions, increasing neglect of worker health policies, growing delays in disease diagnosis, and rising cases of untreated respiratory issues.

The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth projected for the forecast period is driven by an increased focus on occupational health standards, stricter enforcement of dust control regulations, more investments in worker safety initiatives, greater awareness of pneumoconiosis risks, and improved access to early diagnostic services. Key trends anticipated during the forecast period include advancements in lung imaging technologies, innovations in portable respiratory devices, developments in AI-driven disease detection, increased funding for research into dust-related health issues, and advancements in wearable air quality monitoring sensors.

The widespread prevalence of smoking is expected to drive the growth of the pneumoconiosis market. Smoking involves inhaling and exhaling the smoke from burning tobacco products such as cigarettes, cigars, or pipes, which releases harmful chemicals that negatively impact the lungs, heart, and overall health. The rising prevalence of smoking is linked to increasing nicotine dependence and continued tobacco use across various age groups. Smoking contributes to pneumoconiosis by raising the incidence of lung diseases related to smoking. For example, in June 2023, The Guardian reported that 14.5% of 14 to 17-year-olds in the UK had used vaping products in early 2023, an increase from 11.8% in 2022. This growing smoking rate is driving the pneumoconiosis market forward.

Increasing healthcare expenditures are expected to contribute to the growth of the pneumoconiosis market. Healthcare expenditures represent the total financial outlay on medical services, treatments, and health-related products by individuals, governments, and organizations. The rising healthcare spending is mainly due to the growing incidence of chronic diseases, which require ongoing treatment and management. These expenditures support pneumoconiosis care by financing early diagnoses, continuous medical care, respiratory therapy, and access to specialized treatments and medications. For example, the Office for National Statistics reported in May 2024 that healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will accelerate the pneumoconiosis market's growth.

Leading companies in the pneumoconiosis market are focusing on the development of targeted drugs, such as oral small molecule drugs, to offer innovative treatment options that improve disease management and enhance the quality of life for those affected by occupational lung diseases. Oral small molecule drugs are made from low molecular weight compounds that can be ingested, absorbed into the bloodstream, and designed to target specific biological processes or proteins to treat diseases. For instance, in March 2022, Sino Biopharmaceutical Limited launched TDI01 suspension, a novel oral small molecule drug targeting ROCK2 for pneumoconiosis treatment. This groundbreaking drug, currently undergoing clinical trials, aims to offer a much-needed therapeutic option for the 900,000 people with pneumoconiosis in China, a condition that previously had no effective treatment.

Major players in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Gilead Sciences, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Veracyte Inc., Fidia Farmaceutici, PharmaMar, Verastem Inc., RS Oncology, Melinta Therapeutics LLC, Lupin

North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumoconiosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumoconiosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumoconiosis market consists of sales of protective equipment, diagnostic imaging systems, and therapeutic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumoconiosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumoconiosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pneumoconiosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumoconiosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pneumoconiosis Market Characteristics

3. Pneumoconiosis Market Trends And Strategies

4. Pneumoconiosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pneumoconiosis Growth Analysis And Strategic Analysis Framework

6. Pneumoconiosis Market Segmentation

7. Pneumoconiosis Market Regional And Country Analysis

8. Asia-Pacific Pneumoconiosis Market

9. China Pneumoconiosis Market

10. India Pneumoconiosis Market

11. Japan Pneumoconiosis Market

12. Australia Pneumoconiosis Market

13. Indonesia Pneumoconiosis Market

14. South Korea Pneumoconiosis Market

15. Western Europe Pneumoconiosis Market

16. UK Pneumoconiosis Market

17. Germany Pneumoconiosis Market

18. France Pneumoconiosis Market

19. Italy Pneumoconiosis Market

20. Spain Pneumoconiosis Market

21. Eastern Europe Pneumoconiosis Market

22. Russia Pneumoconiosis Market

23. North America Pneumoconiosis Market

24. USA Pneumoconiosis Market

25. Canada Pneumoconiosis Market

26. South America Pneumoconiosis Market

27. Brazil Pneumoconiosis Market

28. Middle East Pneumoconiosis Market

29. Africa Pneumoconiosis Market

30. Pneumoconiosis Market Competitive Landscape And Company Profiles

31. Pneumoconiosis Market Other Major And Innovative Companies

32. Global Pneumoconiosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumoconiosis Market

34. Recent Developments In The Pneumoconiosis Market

35. Pneumoconiosis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기